Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
Law
Mansun
M
Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Maruyama
Toshiaki
T
Lewis
Jamie
J
Giang
Erick
E
Tarr
Alexander W
AW
Stamataki
Zania
Z
Gastaminza
Pablo
P
Chisari
Francis V
FV
Jones
Ian M
IM
Fox
Robert I
RI
Ball
Jonathan K
JK
McKeating
Jane A
JA
Kneteman
Norman M
NM
Burton
Dennis R
DR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000939:Epitopes / Q000737:chemistry; D016174:Hepacivirus / Q000378:metabolism*; D006508:Hepatitis Antibodies / Q000737:chemistry*; D006526:Hepatitis C / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D051379:Mice; D009500:Neutralization Tests; D051381:Rats; D013045:Species Specificity; D014761:Viral Hepatitis Vaccines
D000911:Antibodies, Monoclonal; D000939:Epitopes; D006508:Hepatitis Antibodies; D007074:Immunoglobulin G; D014761:Viral Hepatitis Vaccines